drugset
drugset / Trial / NCT03493776

Safety and Immunogenicity of Non-live, Recombinant Subunit Herpes Zoster Vaccine Before and After Lung Transplantation

NCT03493776 ↗

Phase 4 Unknown 50 enrolled Deepali Kumar
Non-randomizedParallel-groupSingle-blindPrevention

Summary

The investigators plan to study the immunogenicity of the vaccine before and after lung transplantation. Patients (at least 50 years old) before and after lung transplantation will be enrolled. The investigators hypothesize that the recombinant varicella-zoster subunit vaccine is able to induce cellular immunogenicity after transplantation.

Timeline

Start
2018-04-15
Primary completion
2019-09-05
Completion
2021-04

Drugs

EvaluationDrugModalityDoseRoute
Subject VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E Vaccine — —

Indications

varicella zoster infection